{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:48:31Z","timestamp":1792756111227,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31770961"],"award-info":[{"award-number":["31770961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107818","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T06:19:48Z","timestamp":1623478788000},"page":"107818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database"],"prefix":"10.1016","volume":"98","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.intimp.2021.107818_b0005","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6382","key":"10.1016\/j.intimp.2021.107818_b0010","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107818_b0015","doi-asserted-by":"crossref","unstructured":"Thompson, A. John, New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. Journal of the National Comprehensive Cancer Network, 2018. 16(5S): p. 594-596.","DOI":"10.6004\/jnccn.2018.0047"},{"key":"10.1016\/j.intimp.2021.107818_b0020","doi-asserted-by":"crossref","unstructured":"L. Kennedy, A. Salama, A review of cancer immunotherapy toxicity, CA: A Cancer J. Clin., 2020. 70(2): p. 86-104.","DOI":"10.3322\/caac.21596"},{"issue":"10","key":"10.1016\/j.intimp.2021.107818_b0025","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107818_b0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J. Thrombosis Haemostasis : JTH"},{"issue":"9","key":"10.1016\/j.intimp.2021.107818_b0035","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.intimp.2021.107818_b0040","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.intimp.2021.107818_b0045","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann. Oncology : Official J. Eur. Soc. Medical Oncol."},{"key":"10.1016\/j.intimp.2021.107818_b0050","article-title":"Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","author":"Moik","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107818_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2021.107818_b0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Invest. New Drugs"},{"issue":"91","key":"10.1016\/j.intimp.2021.107818_b0065","first-page":"164","article-title":"Arterial thrombosis and anti-PD-1 blockade. European journal of cancer (Oxford","volume":"2018","author":"Boutros","year":"1990","journal-title":"England"},{"key":"10.1016\/j.intimp.2021.107818_b0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb. Res."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2021.107818_b0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e20624","article-title":"Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab","volume":"35","author":"Hegde","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2021.107818_b0080","article-title":"Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience","volume":"130","author":"Ibrahimi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107818_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2021.107818_b0090","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.107818_b0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.intimp.2021.107818_b0100","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2021.107818_b0105","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.intimp.2021.107818_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-20315-3_6","article-title":"Thrombotic risk from chemotherapy and other cancer therapies","volume":"179","author":"Debbie Jiang","year":"2019","journal-title":"Cancer Treat. Res."},{"issue":"25","key":"10.1016\/j.intimp.2021.107818_b0115","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncology : Official J. Am. Soc. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2021.107818_b0120","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"issue":"9604","key":"10.1016\/j.intimp.2021.107818_b0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2021.107818_b0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107818_b0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107818_b0140","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncology : Official J. Eur. Soc. Medical Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2021.107818_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010052","article-title":"Comparative efficacy and safety of anti-PD-1\/PD-L1 immune checkpoint inhibitors for refractory or relapsed advanced non-small-cell lung cancer-a systematic review and network meta-analysis","volume":"13","author":"Ando","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2021.107818_b0150","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/jca.49325","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors for patients with solid tumors: a systematic review and bayesian network meta-analysis","volume":"12","author":"Huang","year":"2021","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2021.107818_b0155","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2021.107818_b0160","doi-asserted-by":"crossref","unstructured":"M. Eppihimer, et al., Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells, Microcirculation (New York, N.Y. : 1994), 2002. 9(2): p. 133-45.","DOI":"10.1080\/713774061"},{"issue":"4","key":"10.1016\/j.intimp.2021.107818_b0165","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"issue":"21","key":"10.1016\/j.intimp.2021.107818_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218159","article-title":"Delicate role of PD-L1\/PD-1 axis in blood vessel inflammatory diseases: current insight and future significance","volume":"21","author":"Veluswamy","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2021.107818_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128523","article-title":"PD-1 and tim-3 pathways regulate CD8+ T cells function in atherosclerosis","volume":"10","author":"Qiu","year":"2015","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.intimp.2021.107818_b0180","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-17-0740","article-title":"IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer","volume":"77","author":"Lamichhane","year":"2017","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.107818_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093280","article-title":"Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice","volume":"9","author":"Cochain","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.intimp.2021.107818_b0190","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107818_b0195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.intimp.2021.107818_b0200","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2021.107818_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.intimp.2021.107818_b0210","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2021.107818_b0215","first-page":"79","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms","volume":"84","author":"Coremans","year":"2021","journal-title":"Acta Gastroenterol. Belg."},{"issue":"2","key":"10.1016\/j.intimp.2021.107818_b0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CMR.0000000000000335","article-title":"Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy","volume":"27","author":"Gupta","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.intimp.2021.107818_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108395","article-title":"Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations","volume":"214","author":"Gremese","year":"2020","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107818_b0230","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.120.046702","article-title":"Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome","volume":"142","author":"Zhang","year":"2020","journal-title":"Circulation"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:24:36Z","timestamp":1747308276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921004549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"alternative-id":["S1567576921004549"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107818","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107818"}}